Crude Heparin Market Size Was valued at USD 9.1 Bn in 2024 and is predicted to reach USD 17.8 Bn by 2034 at a 7.2% CAGR during the forecast period for 2025-2034.
Crude heparin is an unprocessed, unrefined form of the anticoagulant medication heparin that is made from animal tissues, usually the lungs and intestines of cattle or pigs. It is a complex mixture of repeating sugar molecules called sulfated glycosaminoglycans. To eliminate contaminants and separate them into distinct fractions based on their molecular weight and activity, crude heparin is subjected to extraction and purification procedures. Since inadequate purification can result in contamination and negative effects, refining is essential to ensuring the safety and effectiveness of crude heparin. The growing incidence of venous thromboembolism (VTE) and other associated conditions is a major factor driving the crude heparin industry. Since the Centers for Disease Control and Prevention (CDC) estimates that 900,000 Americans suffer from VTE annually, there is a significant need for heparin and other effective anticoagulants.
Furthermore, the use of crude heparin to prevent thrombosis during and after surgeries has increased due to the growing number of surgical procedures performed worldwide. A further important aspect driving market expansion is the growing geriatric population. The demand for crude heparin is expected to increase due to the higher risk of cardiovascular diseases in older adults, presenting a significant market opportunity for those involved in its production and distribution.
However, the market for crude heparin is subject to several limitations that could hinder its growth, despite its encouraging development potential. One of the main concerns is the moral and legal dilemmas associated with the source of heparin. Concerns about sustainability and animal welfare are raised by the growing scrutiny of products derived from animals, which may lead to public opposition. Additionally, the market is susceptible to supply chain disruptions, as demonstrated during the COVID-19 pandemic, when acquiring raw materials proved challenging and impacted manufacturing schedules.
Competitive Landscape
Some of the Major Key Players in the Crude Heparin Market are
- Shenzhen Hepalink Pharmaceutical Group
- Fengrun Biological Technology
- Hepac (Darling Ingredients)
- Yantai Dongcheng Biochemicals
- Hebei Changshan Biochemical Pharmaceutical
- Changzhou Qianhong Biopharma
- Pharma Action (Tönnies Group)
- Nanjing King-friend Biochemical Pharmaceutical
- Aspen Oss
- Huaian MDC Pharmaceutical
- Others
Market Segmentation:
The crude heparin market is segmented based on source, application, formulation type, end-user, and distribution channel. Based on source, the market is segmented into porcine heparin and bovine heparin. By application, the market is segmented into surgical procedures, orthopedic, cardiovascular, and oncology. By formulation type, the market is segmented into injectable heparin and non-injectable formulations. By end-user, the market is segmented into hospitals, clinics, and long-term care facilities. By distribution channel the market is segmented into direct sales, pharmacies, online sales, and wholesalers.
Based On The Source, The Porcine Heparin Segment Is Accounted As A Major Contributor To The Crude Heparin Market
The porcine heparin segment is expected to hold a major global market share in 2024 owing to the increased heparin output and purity obtained from pig intestines. The market for heparin from pigs has remained dominant because of its broad acceptability and long history of use in pharmaceutical applications. Well-established supply chains and manufacturing techniques facilitate this segment's sustained expansion. However, in other areas, religious prohibitions and animal welfare concerns have prompted research into alternative sources, such as bovine heparin.
On the other hand, bovine heparin, derived from cattle, is gaining popularity in areas where pig sources are restricted. Bovine heparin is a safe substitute for heparin obtained from pigs, and its return is largely due to improvements in purification technologies that ensure the elimination of any impurities. The increased availability of cattle in some areas, which offers a reasonably priced source of raw materials, is another factor driving the rising demand for bovine heparin.
Hospitals Segment To Witness Growth At A Rapid Rate
One of the main end-user segments is hospitals, where heparin is widely utilized in clinical settings to treat and prevent blood clotting disorders. The high frequency of surgical procedures and the vital requirement for anticoagulant therapy in postoperative care are the reasons behind the hospital segment's dominance. The need for heparin in hospital settings is further fueled by the growing incidence of cardiovascular illnesses and the rise in hospital admissions for associated ailments.
In The Region, The North American Crude Heparin Market Holds A Significant Revenue Share
The North American crude heparin market is expected to register the highest market share in revenue in the near future because of its robust pharmaceutical sector and sophisticated healthcare system. Due to the high incidence of cardiovascular disorders and the rising number of surgical procedures, the United States holds a significant market share. The presence of significant pharmaceutical firms and research facilities in North America contributes to the market's expansion by fostering innovation and the development of novel heparin-based treatments.
In addition, Asia Pacific is projected to grow rapidly in the global crude heparin market driven by the healthcare industry's explosive growth in nations like China and India, where rising healthcare costs and better healthcare infrastructure are commonplace. The Asia Pacific region is a desirable location for the manufacture and use of heparin due to the availability of affordable labor & raw materials, as well as encouraging government initiatives. The market's growth in this area is further aided by the increasing incidence of lifestyle-related illnesses and the increased knowledge of anticoagulant treatments.
Recent Development:
- May 2023: The Vall business and the Spanish pharmaceutical business Bioiberica S.A.U. Formed a joint venture with the goal of manufacturing crude heparin that is derived from the intestinal mucosa of pigs. Through their strategic alliance, Bioiberica improves the heparin supply chain by combining its knowledge of biochemistry with Vall Company's animal processing skills. Because crude heparin is the primary ingredient in the synthesis of low molecular weight heparin for various anticoagulant treatments, Bioiberica S.A.U. and Vall Companys have partnered to increase production capacity and provide dependable, high-quality crude heparin supplies. This business uses effective and sustainable extraction methods to meet the growing demand for heparin-based goods on the global market.
Crude Heparin Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 9.1 Bn |
|
Revenue Forecast In 2034 |
USD 17.8 Bn |
|
Growth Rate CAGR |
CAGR of 7.2% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Source, By Application, By Formulation Type, By End-User, By Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Shenzhen Hepalink Pharmaceutical Group, Fengrun Biological Technology, Hepac (owned by Darling Ingredients), Yantai Dongcheng Biochemicals, Hebei Changshan Biochemical Pharmaceutical, Changzhou Qianhong Biopharma, Pharma Action (part of Tönnies Group), Nanjing King-friend Biochemical Pharmaceutical, Aspen Oss, Huaian MDC Pharmaceutical, and others. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
